Company Overview of Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense (3GA) technology. The company’s lead drug candidate is IMO-8400, which is in Phase I/II clinical trials for the treatment of Waldenström’s Macroglobulinemia and diffuse large B-cell lymphoma, as well as in Phase II clinical trial for the treatment of dermatomyositis. Its drug candidates also comprise IMO-9200, a dru...
167 Sidney Street
Cambridge, MA 02139
Founded in 1989
Key Executives for Idera Pharmaceuticals, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $600.0K
Chief Financial Officer, Senior Vice President of Operations, Treasurer and Assistant Secretary
Total Annual Compensation: $337.4K
President of Research and Director
Total Annual Compensation: $588.1K
Senior Vice President, General Counsel and Secretary
Total Annual Compensation: $182.7K
Senior Vice President of Business Development & Strategic Planning
Total Annual Compensation: $336.8K
Compensation as of Fiscal Year 2015.
Idera Pharmaceuticals, Inc. Key Developments
Idera Pharmaceuticals, Inc. Reports Translational Data Supporting the Mechanism of Action of Intratumoral IMO-2125
Nov 11 16
Idera Pharmaceuticals, Inc. is reporting translational data supporting the mechanism of action of intratumoral IMO-2125, a Toll-like receptor (TLR) 9 agonist from the ongoing Phase 1 dose escalating clinical trial. In this trial, IMO-2125 is being evaluated in combination with ipilimumab for treatment of patients with metastatic melanoma with disease that is refractory to anti-PD-1 inhibitors, and have minimal options and low expectation of clinical response with ipilimumab treatment alone. Taken together, the previously reported early clinical responses and the supporting mechanism of action translational data being presented on Nov. 11, 2016, indicate that intratumoral IMO-2125 is a potent agent for the stimulation of the tumor microenvironment. Immunological analysis of the biopsy taken from the lesion injected with IMO-2125 showed rapid dendritic cell maturation which is a critical first step in the induction of the immune cascade within the tumor microenvironment. During the treatment period, T-cell expansion and activation and importantly, immune infiltration was observed in the biopsied distant lesions of the responding patients, demonstrating the abscopal effect. From a clinical perspective, through all dosing cohorts tested to date, no dose-limiting toxicity has been seen. Preliminary clinical activity is also encouraging in this population with disease that is refractory to PD-1 inhibitors as 3 responses (including one CR) have already been recorded. The trial continues to dose escalate and enrollment into the planned anti-PD-1 inhibitor combination arm has also commenced. These early results are from the phase 1 portion of study IMO-2125-204 (NCT02644967) in which cohorts of patients with metastatic melanoma unresponsive to PD-1 inhibitor therapy are being administered escalating doses of IMO-2125 ranging from 4 mg/kg through 32 mg/kg. IMO-2125 is injected intra-tumorally into a designated tumor lesion together with a standard dosing regimen of ipilimumab. The trial has recently been amended to also study the combination of IMO-2125 and pembrolizumab given intravenously. Following determination of the recommended phase 2 doses (RP2D) additional patients will be treated in an expansion phase 2 portion of the study. The primary objective of the phase 1 portion of the trial is to characterize the safety and determine a RP2D of IMO-2125 when administered intra-tumorally in combination with ipilimumab or pembrolizumab. The primary objective of the phase 2 portion is to assess the clinical activity of IMO-2125 in each combination at the respective RP2Ds. Assessment will be based on the immune-related response criteria (irRC) and additionally the traditional RECIST criteria. Serial biopsies are being taken of selected injected and non-injected tumor lesions to assess immune changes and correlate with clinical response assessments. The trial will enroll approximately 60 patients. The study is being conducted at MD Anderson and is being led by Adi Diab, MD, Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, MD Anderson as part of a strategic research alliance announced by Idera and MD Anderson in 2015.
Idera Pharmaceuticals, Inc. Presents at Stifel 2016 Healthcare Conference, Nov-16-2016 03:00 PM
Oct 29 16
Idera Pharmaceuticals, Inc. Presents at Stifel 2016 Healthcare Conference, Nov-16-2016 03:00 PM. Venue: Lotte New York Palace Hotel, New York, New York, United States. Speakers: Vincent J. Milano, Chief Executive Officer, President and Director.
Idera Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016
Oct 28 16
Idera Pharmaceuticals, Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2016. For the quarter, net loss was $12.9 million or $0.10 per basic and diluted share compared to $11.3 million or $0.10 per basic and diluted share for the same period in 2015. Alliance revenue was $323,000 against $20,000 for the same period of last year. Loss from operations was $12,977,000 against $11,464,000 for the same period of last year.
For the nine months, the company's net loss was $39.2 million or $0.32 per basic and diluted share compared to $36.5 million or $0.32 per basic and diluted share for the same period in 2015. Alliance revenue was $918,000 against $59,000 for the same period of last year. Loss from operations was $39,500,000 against $36,763,000 for the same period of last year.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|